Related Experiment Video
Updated: May 20, 2026
04:41
Preparation of Oligomeric β-amyloid1-42 and Induction of Synaptic Plasticity Impairment on Hippocampal Slices
Published on: July 14, 2010
Neurotoxicity of amyloid β-protein: synaptic and network dysfunction
Lennart Mucke1, Dennis J Selkoe
1Gladstone Institute of Neurological Disease and University of California, San Francisco, San Francisco, California, USA. lmucke@gladstone.ucsf.edu
Cold Spring Harbor Perspectives in Medicine
|July 5, 2012
Summary
Amyloid beta (Aβ) assemblies bind to cell membranes, triggering diverse neurotoxic pathways. This complex molecular interaction underlies synaptic dysfunction and cognitive decline in disorders like Alzheimer's disease.
Area of Science:
- Neuroscience
- Molecular Biology
- Biochemistry
Background:
- Amyloid beta (Aβ) protein is implicated in neurodegenerative diseases.
- A growing number of molecular mediators contribute to Aβ neurotoxicity.
- Aβ binding to cellular membranes initiates multifaceted cellular effects.
Purpose of the Study:
- To explore the diverse molecular mechanisms of Aβ neurotoxicity.
- To understand how Aβ assemblies interact with neuronal membranes.
- To investigate the link between Aβ-induced synaptic dysfunction and cognitive impairment.
Main Methods:
- Utilizing electrophysiology to study neuronal activity.
- Employing synaptic biochemistry to analyze molecular interactions.
- Conducting behavioral phenotyping in animal models.
Main Results:
- Evidence suggests multiple Aβ assembly forms interact with various membrane components.
- Aβ binding triggers complex synaptic dysfunction and network disorganization.
- These molecular events correlate with progressive cognitive decline.
Conclusions:
- Aβ neurotoxicity involves a complex interplay of molecular mediators and assembly forms.
- Understanding these interactions is crucial for developing therapeutic interventions.
- Modern research integrates multiple disciplines to unravel Aβ's pathological role.
Related Concept Videos
01:23Alzheimer Disease ll: Pathophysiology
Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...
03:03Amyloid Fibrils
Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining, normally used to...
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining, normally used to...
03:03Amyloid Fibrils
Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining, normally used to...
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining, normally used to...
01:26Alzheimer's Disease: Overview
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
01:24Parkinson Disease ll: Pathophysiology
Parkinson disease (PD) is a progressive neurodegenerative disorder primarily affecting movement, with additional non-motor features. Its pathophysiology involves complex interactions among genetic susceptibility, environmental exposures, and cellular dysfunction, including dopaminergic neuron loss, protein aggregation, and mitochondrial impairment.Selective NeurodegenerationA key feature is the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced...
01:22Dementia l: Introduction
Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...